
Zsuzsanna Nagy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5602346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis. PLoS ONE, 2022, 17, e0267183.	2.5	7
2	The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer. Cancers, 2021, 13, 310.	3.7	10
3	A breakthrough-like effect of metformin reduces peripheral resistance to triiodothyronine in euthyroid, non-insulin-resistant, type 2 diabetic patients. Endocrine Connections, 2021, 10, 782-788.	1.9	2
4	ILB® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis. Journal of Personalized Medicine, 2021, 11, 794.	2.5	7
5	An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. Journal of Pathology: Clinical Research, 2020, 6, 308-319.	3.0	10
6	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight, 2020, 5, .	5.0	23
7	A Network Biology Approach Identifies Molecular Cross-Talk between Normal Prostate Epithelial and Prostate Carcinoma Cells. PLoS Computational Biology, 2016, 12, e1004884.	3.2	5
8	The Effects of Two Polymorphisms on p21cip1 Function and Their Association with Alzheimer's Disease in a Population of European Descent. PLoS ONE, 2015, 10, e0114050.	2.5	16
9	Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis, 2015, 18, 83-95.	7.2	15
10	Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt–Hogg–Dubé tumour suppressor gene (FLCN). Oncogene, 2014, 33, 956-965.	5.9	8
11	Abstract LB-256: Immunotherapy using genetically modified T lymphocytes to target CLEC14A on the tumor vasculature. Cancer Research, 2014, 74, LB-256-LB-256.	0.9	1
12	Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 3.	5.2	55
13	Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability. Human Molecular Genetics, 2013, 22, 203-217.	2.9	49
14	ldentification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene, 2012, 31, 293-305.	5.9	91
15	Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene. Molecular Cancer Therapeutics, 2011, 10, 80-89.	4.1	18
16	Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane. British Journal of Cancer, 2009, 101, 957-966.	6.4	13
17	Presence of the APOE ε4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine–Syracuse Study. Diabetologia, 2009, 52, 2551-2560.	6.3	76
18	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 2008, 9, 201.	2.8	56

ZSUZSANNA NAGY

#	Article	IF	CITATIONS
19	Homocysteine and cognitive performance: Modification by the ApoE genotype. Neuroscience Letters, 2008, 430, 64-69.	2.1	46
20	The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 402-408.	3.8	30
21	Alpha-synuclein pathology in the olfactory pathways of dementia patients. Journal of Anatomy, 2007, 211, 117-124.	1.5	87
22	Homocysteine, Folate, and Vitamins B6 and B12 Blood Levels in Relation to Cognitive Performance: The Maine-Syracuse Study. Psychosomatic Medicine, 2006, 68, 547-554.	2.0	78
23	The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2005, 9, 531-541.	3.6	52
24	Depressive Symptoms Increase the Likelihood of Cognitive Impairment in Elderly People with Subclinical Alzheimer Pathology. Dementia and Geriatric Cognitive Disorders, 2005, 19, 46-50.	1.5	14
25	Cell Cycle Activation and Cell Death in the Nervous System. , 2005, , 42-54.		0
26	Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy Bodies. American Journal of Psychiatry, 2004, 161, 843-849.	7.2	130
27	Cell Cycle-Related Protein Expression in Alzheimer's Disease and Vascular Disease. International Psychogeriatrics, 2003, 15, 77-79.	1.0	3
28	Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain, 2002, 125, 1772-1781.	7.6	177
29	Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neuroscience Letters, 2002, 317, 81-84.	2.1	43
30	Evidence for a role for apoptosis in central pontine myelinolysis. Acta Neuropathologica, 2002, 103, 590-598.	7.7	60
31	New temperature modification makes the Bielschowsky silver stain reproducible. Acta Neuropathologica, 2001, 101, 17-21.	7.7	50
32	Constructional Apraxia in Alzheimer's Disease: Association with Occipital Lobe Pathology and Accelerated Cognitive Decline. Dementia and Geriatric Cognitive Disorders, 2001, 12, 281-288.	1.5	29
33	Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 739-743.	1.9	124
34	Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clinical Endocrinology, 2000, 53, 337-344.	2.4	54
35	Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. British Journal of Cancer, 2000, 82, 1441-1445.	6.4	81
36	Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Human Genetics, 2000, 106, 447-452.	3.8	48

ZSUZSANNA NAGY

#	Article	IF	CITATIONS
37	Coexisting pathologies in the brain: influence of vascular disease and Parkinson's disease on Alzheimer's pathology in the hippocampus. Acta Neuropathologica, 2000, 100, 87-94.	7.7	15
38	Diagnosing Dementia: Interrater Reliability Assessment and Accuracy of the NINCDS/ADRDA Criteria versus CERAD Histopathological Criteria for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 107-113.	1.5	43
39	Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. Journal of Endocrinology, 2000, 165, 475-481.	2.6	93
40	Cell cycle regulatory failure in neurones: causes and consequences. Neurobiology of Aging, 2000, 21, 761-769.	3.1	92
41	Hyperhomocysteinaemia in Alzheimer's disease and expression of cell cycle markers in the brain. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 565-566.	1.9	19
42	Angiogenesis in Pituitary Adenomas and the Normal Pituitary Gland. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1159-1162.	3.6	38
43	Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2931-2935.	3.6	22
44	The Progression of Alzheimer's Disease from Limbic Regions to the Neocortex: Clinical, Radiological and Pathological Relationships. Dementia and Geriatric Cognitive Disorders, 1999, 10, 115-120.	1.5	71
45	The enhanced peroxidase one step method increases sensitivity for detection of Ki-67 in pituitary tumours. Journal of Clinical Pathology, 1999, 52, 624-626.	2.0	5
46	Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathologica, 1999, 97, 346-354.	7.7	83
47	Cell cycle-related protein expression in vascular dementia and Alzheimer's disease. Neuroscience Letters, 1999, 271, 45-48.	2.1	93
48	Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet, The, 1999, 354, 919-920.	13.7	457
49	Relationship between Clinical and Radiological Diagnostic Criteria for Alzheimer's Disease and the Extent of Neuropathology as Reflected by †Stages': A Prospective Study. Dementia and Geriatric Cognitive Disorders, 1999, 10, 109-114.	1.5	43
50	Reply to Korr. Acta Neuropathologica, 1998, 95, 553-553.	7.7	0
51	Discussion. Neuroscience, 1998, 87, 731-739.	2.3	148
52	Neuronal Cyclin Expression in the Hippocampus in Temporal Lobe Epilepsy. Experimental Neurology, 1998, 150, 240-247.	4.1	55
53	Temporal Cortex Synaptophysin mRNA Is Reduced in Alzheimer's Disease and Is Negatively Correlated with the Severity of Dementia. Experimental Neurology, 1998, 150, 235-239.	4.1	53
54	Assessment of the Pathological Stages of Alzheimer's Disease in Thin Paraffin Sections: A Comparative Study. Dementia and Geriatric Cognitive Disorders, 1998, 9, 140-144.	1.5	40

ZSUZSANNA NAGY

#	Article	IF	CITATIONS
55	Comparison of Pathological Diagnostic Criteria for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 182-189.	1.3	37
56	Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer's Disease in Relation to Different Pathological Diagnostic Protocols. Dementia and Geriatric Cognitive Disorders, 1998, 9, 219-226.	1.5	82
57	Staging of Alzheimer-Type Pathology: An Interrater-Intrarater Study. Dementia and Geriatric Cognitive Disorders, 1997, 8, 248-251.	1.5	32
58	The Effects of Additional Pathology on the Cognitive Deficit in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 165-170.	1.7	196
59	Effect of Desferrioxamine Cardioplegia on Ischemia-Reperfusion Injury in Isolated Rat Heart. Annals of Thoracic Surgery, 1997, 63, 1003-1011.	1.3	18
60	Apoptosis-Related Protein Expression in the Hippocampus in Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 565-571.	3.1	107
61	Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathologica, 1997, 93, 294-300.	7.7	210
62	Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathologica, 1997, 94, 6-15.	7.7	297
63	Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet, The, 1996, 348, 483-484.	13.7	30
64	8 Acetylcholinesterase in cerebrospinal fluid in relation to histopathological diagnosis of Alzheimer's disease and apolipoprotein E allelotype. Neurobiology of Aging, 1996, 17, S2-S3.	3.1	0
65	451 SPET (99mTc-HMPAO) and X-ray CT in the diagnosis of Alzheimer's disease: Improved accuracy over clinical criteria in a cohort of 114 prospectively evaluated subjects with histopathological diagnoses. Neurobiology of Aging, 1996, 17, S112.	3.1	1
66	Hippocampal Pathology Reflects Memory Deficit and Brain Imaging Measurements in Alzheimers Disease: Clinicopathologic Correlations Using Three Sets of Pathologic Diagnostic Criteria. Dementia and Geriatric Cognitive Disorders, 1996, 7, 76-81.	1.5	53
67	Clustering of Pathological Features in Alzheimers Disease: Clinical and Neuroanatomical Aspects. Dementia and Geriatric Cognitive Disorders, 1996, 7, 121-127.	1.5	7
68	Relative Roles of Plaques and Tangles in the Dementia of Alzheimer's Disease: Correlations Using Three Sets of Neuropathological Criteria. Dementia and Geriatric Cognitive Disorders, 1995, 6, 21-31.	1.5	156
69	Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience, 1995, 69, 757-761.	2.3	229